Literature DB >> 3663480

Response of spheroids implanted in the peritoneal cavity of mice exposed to cyclophosphamide and ionizing radiation.

P L Olive1.   

Abstract

Chinese hamster V79-171B spheroids implanted in the peritoneal cavity of C3H mice were characterized as a model for evaluating the toxicity of drugs requiring metabolic activation in vivo. After 24 hours in the peritoneal cavity, spheroid cellularity and plating efficiency were not significantly decreased, and host cell infiltration was estimated between 5 and 10%. The oxygenation of spheroids in the peritoneal cavity was assessed using their response to ionizing radiation. Spheroids were recovered after irradiation, incubated for 20 minutes in vitro with the slowly penetrating fluorescent dye, Hoechst 33342, and reduced to single cells with trypsin. Cells were analysed for clonogenicity as a function of position within the spheroid by using fluorescence-activated cell sorting in conjunction with the Hoechst diffusion gradient. When spheroids were first placed in the peritoneal cavity, the hypoxic fraction was close to 100%, but after 24 hours, cell oxygenation increased, probably due to a decrease in cell respiration rate. However, the location of a spheroid within the peritoneal cavity did not influence the radiosensitivity of individual spheroids or the amount of Hoechst 33342 delivered to the spheroid when Hoechst was given intravenously; individual spheroids recovered from mice given an intravenous injection of Hoechst showed no greater heterogeneity in binding than that observed when spheroids were incubated with Hoechst in vitro. Mice implanted with spheroids were also exposed to cyclophosphamide; the external cells of 0.6 mm diameter spheroids were about 30% more sensitive than the internal cells to the toxic effects of both cyclophosphamide and X-rays, and the combination of the two agents was additive at all depths within the spheroid.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3663480      PMCID: PMC2002187          DOI: 10.1038/bjc.1987.196

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  16 in total

1.  Chemosensitivity testing in V79 spheroids: drug delivery and cellular microenvironment.

Authors:  R E Durand
Journal:  J Natl Cancer Inst       Date:  1986-07       Impact factor: 13.506

2.  Patterns of mutagen binding and penetration in multicell spheroids.

Authors:  P L Olive
Journal:  Environ Mutagen       Date:  1986

3.  Use of a cell sorter for assays of cell clonogenicity.

Authors:  R E Durand
Journal:  Cancer Res       Date:  1986-06       Impact factor: 12.701

4.  Use of Hoechst 33342 for cell selection from multicell systems.

Authors:  R E Durand
Journal:  J Histochem Cytochem       Date:  1982-02       Impact factor: 2.479

5.  Assessment of in situ host immunity to syngeneic tumors utilizing the multicellular spheroid model.

Authors:  E M Lord; G Burkhardt
Journal:  Cell Immunol       Date:  1984-05       Impact factor: 4.868

6.  In vitro analysis of the response of multicellular tumor spheroids exposed to chemotherapeutic agents in vitro or in vivo.

Authors:  J M Yuhas; A E Tarleton; J G Harman
Journal:  Cancer Res       Date:  1978-11       Impact factor: 12.701

7.  Oxygen enhancement ratio in V79 spheroids.

Authors:  R E Durand
Journal:  Radiat Res       Date:  1983-11       Impact factor: 2.841

8.  Comparison of in situ and peripheral host immunity to syngeneic tumours employing the multicellular spheroid model.

Authors:  E M Lord
Journal:  Br J Cancer Suppl       Date:  1980-04

9.  Exclusion of an interactive effect of combined x-irradiation and activated cyclophosphamide in tissue culture.

Authors:  J E Byfield; M Lynch; F Kulhanian
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-08       Impact factor: 7.038

10.  Pharmacokinetics, binding and distribution of Hoechst 33342 in spheroids and murine tumours.

Authors:  P L Olive; D J Chaplin; R E Durand
Journal:  Br J Cancer       Date:  1985-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.